Who is sponsoring NCT07224971?

NCT07224971 is sponsored by Liza Villaruz, MD.

What condition does NCT07224971 study?

NCT07224971 studies Advanced/Metastatic NSCLC.

What drugs are being tested in NCT07224971?

Interventions: Immunotherapy - PD-1 Blocker.

What is the status of NCT07224971?

NCT07224971 is currently RECRUITING.

Last reviewed 2025-12-09 · How we verify

Impact of Circadian Rhythm on Immunotherapy

NCT07224971 PHASE2 RECRUITING

This study aims to determine whether morning versus afternoon treatment impacts efficacy of (standard of care) immunotherapy in a broad patient population. Patients with any type of advanced/metastatic malignancy are eligible to enroll in this study, as long as first-line anti-PD-1/PD-L1 immunotherapy is on label for their condition. Participants will then be randomized to either the early treatment group (administration must start and conclude by 11:00 AM +1 hour window) or the late treatment group (administration must start after 12:00 PM).

Details

Lead sponsor	Liza Villaruz, MD
Phase	PHASE2
Status	RECRUITING
Enrolment	350
Start date	Tue Dec 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed May 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Advanced/Metastatic NSCLC

Interventions

Immunotherapy - PD-1 Blocker

Countries

United States